HCPLive Network

Product News

Clinicians who treat patients suffering with osteoarthritis pain have a new low-dose nonsteroidal anti-inflammatory drug (NSAID) option at their disposal. Zorvolex (diclofenac) was developed to meet prevailing FDA recommendations regarding NSAID dosing and treatment duration.
One-pill regiment includes abacavir, dolutegravir and lamivudine.
Eliquis is also now indicated for reducing the risk of recurrent DVT and PE following initial therapy.
Between developing its own pipeline of therapies for patients with hepatitis C and acquiring another company known for its work in this field, it looks like Merck is taking steps to be a larger player in HCV market.
A new drug was given tentative approval by the US Food and Drug Administration to help patients with both type 1 and type 2 diabetes.
Fixed-dose tablet is the first sodium glucose cotransporter 2 (SGLT2) inhibitor plus metformin combo product to receive approval in the US.
Orbactiv (oritavancin) is a new antibacterial drug approved to treat patients with acute bacterial skin and skin structure infections.
The US Food and Drug Administration announced the approval of Jardiance (empagliflozin) to treat adults with type 2 diabetes.
The US Food and Drug Administration announced the approval of a new drug for the treatment of chronic obstructive pulmonary disease.